News on Fda.Jp
There has been 72 news on Fda.Jp in the past from 20 sources across 4 sections.
Access to all news on this scope:
See the trend on this scope:
Evolution through time
Sentiment analysis
Current sentiment polarity: neutral with a score of 0
Sentiment polarity through time
Latest news
VidaSlim products recalled over 'serious or even fatal' poisoning risk: FDA
Supreme Court hears arguments over FDA's refusal to approve flavored e-cigarettes
Supreme Court grapples with FDA's refusal to approve flavored vapes
Supreme Court scrutinizes details of FDA's rejection of marketing for flavored vapes
Justices unconvinced of arguments against FDA's flavored vape ban
Supreme Court Hears Case on FDA's Rejection of Flavored Vapes
New FDA rules require TV drug ads to be more clear and direct
Richard Pazdur, FDA Cancer Chief, Discusses 25 Years of Innovation
Heritage study suggests ER visits from abortion pills rose after FDA lifted in-person requirement
FDA Names a New Chief of Medical Devices
FDA recalls thousands of antidepressant bottles due to cancer-causing chemical
Trade group sues FDA over ending Mounjaro/Zepbound shortage
Dog food recall update: Salmonella and Listeria fears spark nationwide product withdrawal and FDA warning
FDA expands approval of breast cancer drug Kisqali to earlier-stage patients
FDA expands approval of breast cancer drug Kisqali: What to know
FDA approves Apple AirPod's hearing aid capability
Congresswomen press FDA on why a proposal to ban hair-straightening chemicals is delayed
More people have to show ID to buy tobacco products under a new FDA rule
FDA gives green light to first at-home syphilis test as cases rise
FDA wants to cut sodium in packaged and processed foods by about 20%
FDA Declines to Approve MDMA Therapy, and Seeks Further Study
Sections
The coverage spans across 4 sections:
Sources
There has been 20 news sources reporting on this, including: NBC News (18%), The Hill (17%), The New York Times (12%), CBS (7%), and Fast Company (6%).
Going further
Stay up to date:
Details
This content is available under the CC BY 4.0 license.